Bavarian Nordic A/S
BVNKF
$32.57
Updated: 24/09/2026, 13:38:46
Market Cap
$2.51B
Sector
Healthcare
Industry
Biotechnology
Country
DK
Stock valuation chart
One-year closing share-price history for BVNKF
Company Profile
Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.
USD
OTC
CEO: Paul John Chaplin
Employees: 1,795
Asset Summaries
Latest generated summaries for BVNKF
No summaries found.
Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for BVNKF.
- Share price
- $32.57
- Market cap
- $2.51B
- Exchange
- OTC
- Currency
- USD
- CEO
- Paul John Chaplin
- Employees
- 1,795
- IPO date
- 15/10/2010
- Beta
- 0.9429999999999999
- Last dividend
- $0.00
- Day range
- $27.56 – $32.57
- 52-week range
- $27.56 – $37.22
- 1-day performance
- 0.00%
- 1-year performance
- 18.18%
- Current drawdown (1Y)
- -12.49%
- CIK
- N/A
- CUSIP
- N/A
- ISIN
- DK0015998017
- Created
- 07/12/2025, 03:09:10
- Last update
- 24/09/2026, 13:38:46
Track Bavarian Nordic A/S with an AI analyst
See which prediction-market events move BVNKF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Latest Database News
News linked to BVNKF from your Railway `news_articles` table.